- Home
- AVIR vs ABEO Comparison
AVIR vs ABEO Comparison
Compare AVIR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | ABEO |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.3M | 399.5M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AVIR | ABEO |
|---|---|---|
| Price | $5.36 | $5.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $20.00 |
| AVG Volume (30 Days) | 255.8K | ★ 1.5M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $2.78 | $4.00 |
| 52 Week High | $6.45 | $7.65 |
Technical Indicators
Market Signals| Indicator | AVIR | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 41.51 |
| Support Level | $5.13 | $5.68 |
| Resistance Level | $5.73 | $5.97 |
| Average True Range (ATR) | 0.24 | 0.27 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 66.67 | 12.82 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.